14Mar
13Mar
Blind Saskatchewan Rush fan, embracing eSight lenses, never misses a play
Every Saskatchewan Rush play is an eye-opening experience for Bobbi Janzen. The legally blind Saskatoon woman has watched every Rush home game this season thanks to pair of eSight glasses she fundraised for last year. “It’s amazing. These are things I didn’t even know existed — from down to the net to the lacrosse sticks themselves, the ball,” Janzen said. “I hadn’t seen a ball in motion in my life, so putting those glasses on and seeing these things, reading jerseys, it...
11Mar
Ergoresearch becomes the reference for the evaluation of knee pain in Quebec
With the support of Ergoresearch, Équilibre—the largest network of orthotists in Quebec , announces the adoption of the latest cutting-edge technology in the management of knee pain: KneeKGTM, which expands the evaluation services it offers in its clinics and knee centres. Read more >>
10Mar
Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) („Corbus” or the „Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2016. Read more >>
09Mar
Siamab Therapeutics Announces Publication of New Preclinical Data
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the publication of new preclinical data describing its novel ST1 antibodies targeting, with high affinity and specificity, the Sialyl-Thomasen-nouveau antigen (STn), a tumor-associated carbohydrate antigen (TACA). Read more >>
09Mar
Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression in...
07Mar
Legally blind Flames fan watches game for first time
Olivia Lettich had been to a Calgary Flames game before, but she watched one for the very first time Sunday. The 11-year-old is legally blind, but thanks to eSight she was able to take in the sounds, and sights, of her favorite hockey team. Read more >>
04Mar
See That Smile
Forget virtual reality; Christian Cardenas is seeing in actual reality for the first time. “I can see you,” Christian told Jeff Fenton, marketing director for eSight, as he turned on Christian’s new eSight glasses. Christian was not shy about telling everyone Friday morning he could see them, and it was not just their shapes and voices registering. He was seeing them for the first time. Read more >>
02Mar
Skyline Medical Awarded Innovative Technology Contract from Vizient, Inc. for STREAMWAY® System
Skyline Medical Inc. (SKLN) (“Skyline” or “the Company”),producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal has received an Innovative Technology contract from Vizient, Inc. Read more >>
02Mar